This is a consistent finding with others who showed patients with triple-negative breast cancers behave less favorably than luminal breast cancers and almost as poorly as HER2/neu over-expressing cancers in terms of locoregional recurrence following BCS [3]. This evidence concerns the gene ERBB2 and breast cancer.